LONSARIS Canadian Trademark Information

On Tuesday, November 6, 2012, a canadian trademark registration was filed for LONSARIS by ALKERMES PHARMA IRELAND LIMITE *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1601198. The current status of this trademark filing is Registration published. The LONSARIS trademark is filed in the description of Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, namely psychiatric disorders, namely schizophrenia, bipolar disorder, depressive disorders, psychosis, irritability associated with autistic disorder, and reward disorders, namely eating disorders; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of neurodegenerative diseases, namely Parkinson's disease and amyotrophic lateral sclerosis (ALS); Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of cardiovascular diseases; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of metabolic diseases, namely diabetes, dyslipidemia and obesity. , Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, namely psychiatric disorders, namely schizophrenia, bipolar disorder, depressive disorders, psychosis, irritability associated with autistic disorder, and reward disorders, namely eating disorders; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of neurodegenerative diseases, namely Parkinson's disease and amyotrophic lateral sclerosis (ALS); Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of cardiovascular diseases; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of metabolic diseases, namely diabetes, dyslipidemia and obesity. , Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, namely psychiatric disorders, namely schizophrenia, bipolar disorder, depressive disorders, psychosis, irritability associated with autistic disorder, and reward disorders, namely eating disorders; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of neurodegenerative diseases, namely Parkinson's disease and amyotrophic lateral sclerosis (ALS); Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of cardiovascular diseases; Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of metabolic diseases, namely diabetes, dyslipidemia and obesity. .